Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Time Course of Drug Effect01:14

Time Course of Drug Effect

2.9K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Survival and Risk of Second Malignant Neoplasms Among Childhood Cancer Patients in 16 Provinces of Spain.

Cancers·2026
Same author

The Lipid-binding PX Domain of RRC-1 (ARHGAP32/33) is Required for Optimal Assembly and Function of Integrin Adhesion Complexes at the Muscle Cell Boundary in C. elegans.

G3 (Bethesda, Md.)·2026
Same author

Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease.

Journal of clinical medicine·2026
Same author

Improving Risk Stratification for SLNB in Elderly Patients With Melanoma: The SENTINOLD Nomogram.

International journal of dermatology·2026
Same author

The Lipid-binding PX Domain of RRC-1 (ARHGAP32/33) is Required for Optimal Assembly and Function of Integrin Adhesion Complexes at the Muscle Cell Boundary in C. elegans.

bioRxiv : the preprint server for biology·2025
Same author

Sequential CO<sub>2</sub> Laser and 5-Fluorouracil for Palliative Management of Cutaneous Squamous Cell Carcinoma.

The Australasian journal of dermatology·2025

Related Experiment Video

Updated: Mar 17, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

994

Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale

Laida Elberdín1, Maria Outeda2, Pilar Salvador2

  • 1Pharmacy Department, A Coruña University Hospital Complex, Integrated Administration Management, As Xubias, 86, 15006, A Coruña, Spain. laida.elberdin@gmail.com.

International Journal of Clinical Pharmacy
|July 21, 2016
PubMed
Summary
This summary is machine-generated.

This study found a positive correlation between etanercept serum levels and improved Psoriasis Area and Severity Index scores in psoriatic patients. Anti-etanercept antibodies were rarely detected, suggesting etanercept is generally safe and effective for psoriasis treatment.

Keywords:
Anti-etanercept antibodiesEtanerceptPsoriasisSerum trough levels

More Related Videos

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
13:02

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis

Published on: November 4, 2017

9.3K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Related Experiment Videos

Last Updated: Mar 17, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

994
Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis
13:02

Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis

Published on: November 4, 2017

9.3K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacokinetics

Background:

  • Limited studies link biological therapies and antidrug antibodies to clinical response in psoriatic patients.
  • Previous evidence has not established a relationship between etanercept levels and treatment outcomes.
  • This study investigates the correlation between etanercept serum levels, anti-etanercept antibodies, and clinical response in psoriasis.

Purpose of the Study:

  • To determine the correlation between etanercept serum levels and clinical response in psoriatic patients.
  • To assess the presence of anti-etanercept antibodies and their impact on treatment efficacy.
  • To evaluate the relationship between etanercept concentration, antibody presence, and adverse reactions.

Main Methods:

  • Retrospective observational study of psoriatic patients treated with etanercept (50 mg weekly).
  • Psoriasis Area and Severity Index (PASI) scores and adverse reactions were recorded.
  • Serum etanercept and anti-etanercept antibody levels were quantified using ELISA; patients were grouped by response (good, partial, non-responders).

Main Results:

  • A positive correlation was observed between higher etanercept concentrations and a greater percentage decrease in PASI scores (p=0.011).
  • No significant difference in etanercept levels was found among good, partial, and non-responders (p=0.085).
  • Anti-etanercept antibodies were not detected in any patient, and adverse effects showed no significant difference (p=0.8523).

Conclusions:

  • Etanercept concentration positively correlates with clinical improvement in psoriatic patients, as measured by PASI score reduction.
  • The incidence of anti-etanercept antibodies in psoriatic patients treated with etanercept appears to be low.
  • These findings support the use of etanercept for psoriasis management, with a low risk of antibody formation.